Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 2/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.41 |
| ▸ | ITGAL | P20701 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1986931 | 1.00 | ECE1 (0.43) | ECE1TGFBR1ITGB2ICAM1ITGAL | |
| SCHEMBL1096294 | 0.86 | ECE1 (0.43) | ECE1TGFBR1ITGB2ICAM1ITGAL | |
| SCHEMBL8675912 | 0.84 | ECE1 (0.42) | ECE1TGFBR1ITGB2ICAM1ITGAL | |
| SCHEMBL2514366 | 0.84 | ECE1 (0.42) | ECE1TGFBR1ITGB2ICAM1ITGAL | |
| SCHEMBL1226550 | 0.83 | ECE1 (0.41) | ECE1TGFBR1ITGB2ICAM1ITGAL | |
| SCHEMBL1226547 | 0.83 | ECE1 (0.41) | ECE1TGFBR1ITGB2ICAM1ITGAL | |
| SCHEMBL7777341 | 0.83 | ECE1 (0.41) | ECE1TGFBR1ITGB2ICAM1ITGAL | |
| SCHEMBL3146208 | 0.81 | SMN1; SMN2 (0.46) | CA2 | |
| SCHEMBL4968311 | 0.81 | SMN1; SMN2 (0.46) | CA2 | |
| SCHEMBL4392510 | 0.81 | ECE1 (0.40) | ECE1TGFBR1ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366738-A1 | MOLECULAR VACCINES FOR INFECTIOUS DISEASE | AGILENT TECHNOLOGIES INC (US) | 2024-11-07 | — | — | US | disclosed |
| US-11992518-B2 | Molecular vaccines for infectious disease | AGILENT TECHNOLOGIES, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-10968269-B1 | MHC multimers in borrelia diagnostics and disease | AGILENT TECHNOLOGIES, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210047383-A1 | MHC Multimers in Borrelia Diagnostics and Disease | DAKO DENMARK APS (DK) | 2021-02-18 | — | — | US | disclosed |
| US-20200347103-A1 | MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS | AGILENT TECHNOLOGIES INC (US) | 2020-11-05 | — | — | US | disclosed |
| US-10611818-B2 | MHC multimers in tuberculosis diagnostics, vaccine and therapeutics | AGILENT TECHNOLOGIES, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190314471-A1 | MOLECULAR VACCINES FOR INFECTIOUS DISEASE | AGILENT TECHNOLOGIES, INC. | 2019-10-17 | — | — | US | disclosed |
| US-10369204-B2 | Molecular vaccines for infectious disease | DAKO DENMARK A/S (DK) | 2019-08-06 | — | — | US | disclosed |
| US-20120258126-A1 | Molecular Vaccines for Infectious Disease | DAKO DENMARK A/S (DK) | 2012-10-11 | — | — | US | disclosed |
| US-20110318380-A1 | MHC Multimers in Cancer Vaccines and Immune Monitoring | DAKO DENMARK A/S (DK) | 2011-12-29 | — | — | US | disclosed |
| EP-2337795-A2 | MHC MULTIMERS IN CANCER VACCINES AND IMMUNE MONITORING | Dako Denmark A/S (DK) | 2011-06-29 | — | — | EP | disclosed |
| EP-2254592-A2 | MHC MULTIMERS IN BORRELIA DIAGNOSTICS AND DISEASE | Dako Denmark A/S (DK) | 2010-12-01 | — | — | EP | disclosed |
| EP-2197908-A2 | MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS | Dako Denmark A/S (DK) | 2010-06-23 | — | — | EP | disclosed |
| WO-2010037402-A1 | MOLECULAR VACCINES FOR INFECTIOUS DISEASE | DAKO DENMARK A/S (DK) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010037395-A2 | MHC MULTIMERS IN CANCER VACCINES AND IMMUNE MONITORING | DAKO DENMARK A/S (DK) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010037397-A1 | MHC MULTIMERS IN CMV IMMUNE MONITORING | DAKO DENMARK A/S (DK) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009106073-A2 | MHC MULTIMERS IN BORRELIA DIAGNOSTICS AND DISEASE | DAKO DENMARK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009039854-A2 | MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS | DAKO DENMARK A/S (DK) | 2009-04-02 | — | — | WO | disclosed |
| WO-2007001399-A2 | COMPOSITIONS, SPLICE VARIANTS AND METHODS RELATING TO CANCER SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2003020899-A2 | COMPOSITIONS AND METHODS RELATING TO LUNG SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2003-03-13 | — | — | WO | disclosed |